Cargando…
A comprehensive review of COVID-19 characteristics
In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402395/ https://www.ncbi.nlm.nih.gov/pubmed/32774178 http://dx.doi.org/10.1186/s12575-020-00128-2 |
_version_ | 1783566749182984192 |
---|---|
author | Esakandari, Hanie Nabi-Afjadi, Mohsen Fakkari-Afjadi, Javad Farahmandian, Navid Miresmaeili, Seyed-Mohsen Bahreini, Elham |
author_facet | Esakandari, Hanie Nabi-Afjadi, Mohsen Fakkari-Afjadi, Javad Farahmandian, Navid Miresmaeili, Seyed-Mohsen Bahreini, Elham |
author_sort | Esakandari, Hanie |
collection | PubMed |
description | In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested by several symptoms, ranging from asymptomatic/mild symptoms to severe illness and death. The viral infection expanded internationally and WHO announced a Public Health Emergency of International Concern. To quickly diagnose and control such a highly infectious disease, suspicious individuals were isolated and diagnostic/treatment procedures were developed through patients’ epidemiological and clinical data. Early in the COVID-19 outbreak, WHO invited hundreds of researchers from around the world to develop a rapid quality diagnosis, treatment and vaccines, but so far no specific antiviral treatment or vaccine has been approved by the FDA. At present, COVID-19 is managed by available antiviral drugs to improve the symptoms, and in severe cases, supportive care including oxygen and mechanical ventilation is used for infected patients. However, due to the worldwide spread of the virus, COVID-19 has become a serious concern in the medical community. According to the current data of WHO, the number of infected and dead cases has increased to 8,708,008 and 461,715, respectively (Dec 2019 –June 2020). Given the high mortality rate and economic damage to various communities to date, great efforts must be made to produce successful drugs and vaccines against 2019-nCoV infection. For this reason, first of all, the characteristics of the virus, its pathogenicity, and its infectious pathways must be well known. Thus, the main purpose of this review is to provide an overview of this epidemic disease based on the current evidence. |
format | Online Article Text |
id | pubmed-7402395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74023952020-08-05 A comprehensive review of COVID-19 characteristics Esakandari, Hanie Nabi-Afjadi, Mohsen Fakkari-Afjadi, Javad Farahmandian, Navid Miresmaeili, Seyed-Mohsen Bahreini, Elham Biol Proced Online Review In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested by several symptoms, ranging from asymptomatic/mild symptoms to severe illness and death. The viral infection expanded internationally and WHO announced a Public Health Emergency of International Concern. To quickly diagnose and control such a highly infectious disease, suspicious individuals were isolated and diagnostic/treatment procedures were developed through patients’ epidemiological and clinical data. Early in the COVID-19 outbreak, WHO invited hundreds of researchers from around the world to develop a rapid quality diagnosis, treatment and vaccines, but so far no specific antiviral treatment or vaccine has been approved by the FDA. At present, COVID-19 is managed by available antiviral drugs to improve the symptoms, and in severe cases, supportive care including oxygen and mechanical ventilation is used for infected patients. However, due to the worldwide spread of the virus, COVID-19 has become a serious concern in the medical community. According to the current data of WHO, the number of infected and dead cases has increased to 8,708,008 and 461,715, respectively (Dec 2019 –June 2020). Given the high mortality rate and economic damage to various communities to date, great efforts must be made to produce successful drugs and vaccines against 2019-nCoV infection. For this reason, first of all, the characteristics of the virus, its pathogenicity, and its infectious pathways must be well known. Thus, the main purpose of this review is to provide an overview of this epidemic disease based on the current evidence. BioMed Central 2020-08-04 /pmc/articles/PMC7402395/ /pubmed/32774178 http://dx.doi.org/10.1186/s12575-020-00128-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Esakandari, Hanie Nabi-Afjadi, Mohsen Fakkari-Afjadi, Javad Farahmandian, Navid Miresmaeili, Seyed-Mohsen Bahreini, Elham A comprehensive review of COVID-19 characteristics |
title | A comprehensive review of COVID-19 characteristics |
title_full | A comprehensive review of COVID-19 characteristics |
title_fullStr | A comprehensive review of COVID-19 characteristics |
title_full_unstemmed | A comprehensive review of COVID-19 characteristics |
title_short | A comprehensive review of COVID-19 characteristics |
title_sort | comprehensive review of covid-19 characteristics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402395/ https://www.ncbi.nlm.nih.gov/pubmed/32774178 http://dx.doi.org/10.1186/s12575-020-00128-2 |
work_keys_str_mv | AT esakandarihanie acomprehensivereviewofcovid19characteristics AT nabiafjadimohsen acomprehensivereviewofcovid19characteristics AT fakkariafjadijavad acomprehensivereviewofcovid19characteristics AT farahmandiannavid acomprehensivereviewofcovid19characteristics AT miresmaeiliseyedmohsen acomprehensivereviewofcovid19characteristics AT bahreinielham acomprehensivereviewofcovid19characteristics AT esakandarihanie comprehensivereviewofcovid19characteristics AT nabiafjadimohsen comprehensivereviewofcovid19characteristics AT fakkariafjadijavad comprehensivereviewofcovid19characteristics AT farahmandiannavid comprehensivereviewofcovid19characteristics AT miresmaeiliseyedmohsen comprehensivereviewofcovid19characteristics AT bahreinielham comprehensivereviewofcovid19characteristics |